Ovid Therapeutics Inc

Ovid Therapeutics’ shares edge higher as biotech optimism lifts investors, with the company’s rare‑neurological focus gaining momentum amid sector‑wide gains.

Ovid Therapeutics reports a $0.06 EPS and 800% revenue growth in Q4 2025, secures a $60 M private placement to fund OV329’s expansion into TSC seizures and infantile spasms, and moves OV4071 toward phase‑1 clearance.

Ovid Therapeutics Inc. is a biopharmaceutical company focused on developing treatments for rare neurological disorders, with a commitment to innovation and patient care despite current financial challenges.

Ovid Therapeutics Inc. is struggling financially and facing skepticism from investors, casting doubt on its ability to deliver on its mission to develop treatments for rare neurological disorders.

Ovid Therapeutics Inc’s stock price has experienced significant volatility, raising concerns about the company’s market valuation and future prospects despite its mission to develop treatments for rare neurological disorders.